MedTrace Logo

Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

NCT00417703 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2008-01-24

No results posted yet for this study

Summary

This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per year, it is important to document the sudden increase in intraocular pressure, including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline. This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections.

We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection.

Conditions

  • Choroidal Neovascularization

Sponsors & Collaborators

  • Oklahoma State University Center for Health Sciences

    lead OTHER

Principal Investigators

  • Scott J Westhouse, DO · Oklahoma State University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417703 on ClinicalTrials.gov